The cancer immunotherapy ‘Keytruda’ firmly held its lead in the domestic pharmaceutical market. This is the 5th consecutive quarter from the first quarter of last year that the drug has recorded top sales among all pharmaceuticals in Korea. Also, the new biopharmaceuticals introduced by multinational pharmaceutical companies like ‘Perjeta,’ and ‘Prolia’ showed rapid growth. Among locally developed new drugs, K-cab showed the most rapid growth.

According to the pharmaceutical research firm IQVIA on the 23rd, MDS’s Keytruda recorded the highest sales of 44.1 billion won in the first quarter this year. This is a 27.0% year-on-year increase from the same quarter of the previous year, and comfortably exc